Key Inclusion Criteria:

• Subject is of legal age to participate in the study per the laws of their respective geography.
• Subject is an acceptable candidate for a WATCHMAN FLX Pro device per the approved Instructions for Use.
• Subject is deemed to be suitable for all protocol defined drug regimens in the control and both test arms.
• The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial.
• The subject is able and willing to return for required follow-up visits and examinations.

Key Exclusion Criteria:

• Subject's device implant procedure was aborted.
• Subject has a device margin residual leak > 0mm at time of implant.
• Occurrence of periprocedural complications (major bleeding, systemic embolism, stroke, pericardial effusion requiring intervention) during the implant procedure.
• Subject has a contraindication to one of the three protocol defined drug regimens
• Subject requires long-term anticoagulation therapy for reason other than AF-related stroke risk reduction or requires chronic P2Y12 inhibitor therapy

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 08/12/2024. Questions regarding updates should be directed to the study team contact.